Blood Cancers Completed Phase 1 Trials for Inebilizumab (DB12530)

Also known as: Blood Cancer

IndicationStatusPhase
DBCOND0048268 (Blood Cancers)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01957579A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell MalignanciesTreatment